392
Last Update Posted: 2017-02-28
Recruiting has ended
All Genders accepted | 18 Years-60 Years |
215 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals.
Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients.
Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.
Eligibility
Relevant conditions:
HIV Infections
Cognition Disorders
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov